Selecta Biosciences Inc (NASDAQ:SELB) saw a large drop in short interest in October. As of October 31st, there was short interest totalling 633,900 shares, a drop of 8.2% from the September 30th total of 690,200 shares. Approximately 2.1% of the company’s stock are short sold. Based on an average daily volume of 133,400 shares, the short-interest ratio is currently 4.8 days.
Shares of NASDAQ SELB traded up $0.01 during mid-day trading on Monday, reaching $1.41. 22,300 shares of the company traded hands, compared to its average volume of 348,195. The stock has a market cap of $66.51 million, a PE ratio of -0.48 and a beta of 1.11. The company’s fifty day moving average is $1.52 and its two-hundred day moving average is $1.84. Selecta Biosciences has a fifty-two week low of $1.28 and a fifty-two week high of $6.25.
Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings data on Wednesday, November 13th. The company reported ($0.26) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.02. As a group, sell-side analysts predict that Selecta Biosciences will post -1.23 earnings per share for the current year.
A number of equities research analysts have recently weighed in on SELB shares. Mizuho reaffirmed a “buy” rating and set a $4.00 price target on shares of Selecta Biosciences in a research note on Sunday, August 11th. Stifel Nicolaus reaffirmed a “buy” rating and set a $6.00 price target on shares of Selecta Biosciences in a research note on Friday, November 8th. Zacks Investment Research downgraded Selecta Biosciences from a “buy” rating to a “hold” rating in a research note on Thursday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price target on shares of Selecta Biosciences in a research note on Friday, November 8th. Finally, ValuEngine raised Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Selecta Biosciences has a consensus rating of “Buy” and a consensus price target of $6.80.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses.
Featured Article: Why do companies issue monthly dividends?
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.